In line with the translational mission of our consortium, ECCPS members identified several novel molecular targets in basic research projects, further developed their exploitation through cellular studies and preclinical disease models, and then forwarded these approaches to the clinical arena with early proof-of-concept and finally phase III trials.
Goals: To expand this chain of translational development. We are confident that the identification of several new promising targets by the ECCPS will lead to phase I/II clinical studies testing novel therapeutic approaches (e.g. microRNA therapeutics). The establishment of large national/international networks will strongly support the larger scale clinical trials that are essential to gain approval and implement new therapies. Translational expertise is a unique asset of the ECCPS (Platform B) and we expect an increase of new knowledge and innovation that can be exploited by both established and emerging German and European pharmaceutical and biotechnological partners.